Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra 11:35:25 2024-04-16 am EDT After market 03:58:10 pm
151.1 EUR -0.72% Intraday chart for Merck KGaA 151.1 -0.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck KGaA Rolls Out New Genetic Stability Assay Platform MT
MERCK : A peer group tidy up Alphavalue
Merck Announces Change of Managing Director of Merck Life Science in India CI
Caris Life Sciences Announces Partnership with Merck KGaA to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development CI
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer CI
UBS Raises Merck KGaA PT, Keeps Buy Rating MT
MERCK KGAA : Jefferies keeps its Buy rating ZD
MERCK KGAA : price target raised by UBS CF
MERCK KGAA : Buy rating from UBS ZD
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia DJ
Merck KGaA Spends EUR300 Million on New Bioprocessing Site in South Korea MT
MERCK KGAA : DZ Bank gives a Buy rating ZD
MERCK KGAA : JP Morgan gives a Buy rating ZD
MERCK KGAA : Barclays gives a Buy rating ZD
Deutsche Bank raises target for Merck KGaA to 175 euros - 'Buy' DP
MERCK KGAA : Deutsche Bank remains its Buy rating ZD
MERCK : A weak finish but the 2024 guidance leaves room for positives Alphavalue
MERCK KGAA : Deutsche Bank reiterates its Buy rating ZD
German Equities Rise as ECB Opens Up to Rate Cuts MT
Global markets live: Darktrace, Merck, Meta, Apple, Eli Lilly... Our Logo
MERCK KGAA : Jefferies remains its Buy rating ZD
Merck KGaA Provides Earnings Guidance for the Year 2024 CI
Merck KGaA Proposes Dividend for the Year 2023 CI
Transcript : MERCK Kommanditgesellschaft auf Aktien, Q4 2023 Earnings Call, Mar 07, 2024
MERCK KGAA : Buy rating from Barclays ZD
Chart Merck KGaA
More charts
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
152.2 EUR
Average target price
182 EUR
Spread / Average Target
+19.58%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck KGaA
  5. Merck KGaA's Investigational Multiple Sclerosis Drug Shows Sustained Efficacy In Mid-stage Study